Hemopexin
HPXproteinHemopexin mitigates heme-mediated oxidative injury and inflammation during atherothrombotic plaque destabilization and myocardial ischemia.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleHeme scavenging and oxidative defense; upregulated in ACS plaque inflammation.
Also acts inMyocardial injury
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000110169
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I44
C — confounder / Type-II80
A — assay feasibility68
E — evidence strength30
T1DI (composite)6
Specificity differential (R−C)-36
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(2)
- Biomarker Discovery of Acute Coronary Syndrome Using Proteomic Approach.Molecules (Basel, Switzerland) · 2021 · PMID 33672727 · doi
- Erythrocyte-heme proteins and STEMI: implications in prognosis.Thrombosis and haemostasis · 2017 · PMID 28837209 · doi